Alvotech Reports Record Results for 2024 and Provides Business Update

Total Revenues in 2024 reached $492 million, representing a 427$273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative$291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities. Alvotech will conduct a business update conference call and live webc ...